HPV Vaccine Review By CDC Cmte. Will Likely Consider Parental Choice
Executive Summary
A review of vaccines for human papilloma virus by CDC's Advisory Committee on Immunization Practices will likely involve a discussion of societal issues surrounding the vaccination of adolescents
You may also be interested in...
Gardasil Review: Will HPV Vaccine Be Inoculated Against Plan B Politics?
HHS regulatory decisions on human papilloma virus vaccines will likely face heightened scrutiny following revelations about FDA's decision-making process on the Rx-to-OTC switch application for Plan B
Gardasil Review: Will HPV Vaccine Be Inoculated Against Plan B Politics?
HHS regulatory decisions on human papilloma virus vaccines will likely face heightened scrutiny following revelations about FDA's decision-making process on the Rx-to-OTC switch application for Plan B
ACIP In Brief
Merck Rotateq pricing: CDC estimates the cost-effective ceiling for a three-dose vaccination series of Merck's pending rotavirus vaccine is $67, the agency reported to its Advisory Committee on Immunization Practices Oct. 27. Merck has not set a price for the vaccine, but said it is committed to a level that will assure widespread use and availability. CDC predicts cost-effectiveness of a routine vaccination schedule for Rotateq would be in the same range as Sanofi-Aventis' meningococcal vaccine Menactra. ACIP's rotavirus vaccine working group is recommending universal administration of three doses of the vaccine at two, four and six months of age. Merck expects approval of Rotateq in early 2006. GlaxoSmithKline said it is in discussions with FDA about licensing its rotavirus vaccine Rotarix in the U.S...